To include your compound in the COVID-19 Resource Center, submit it here.

Idorsia insomnia candidate headed for Phase III

Idorsia Ltd. (SIX:IDIA) said ACT-541468 led to a significant, dose-dependent reduction in Wake After Sleep Onset (WASO) from baseline on

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE